Seroprevalence of IgM and IgG in Serum of COVID-19 Diabetic Patients After Recovery.

Abstract

Coronavirus disease (Covid-19) is an infection caused by SARS-CoV-2. Patients experience several symptoms in the respiratory tract following infection. Developing an immunity is essential to protect the host from future infection. In this study we will investigate the seropositivity of IgM and IgG in recovered COVID-19 diabetic patients compared to prediabetic, and non-diabetic. Three hundred and eighty-four recovered COVID-19 patients were enrolled in this study and subdivided according to their glycemic status, 156 diabetic, 77 prediabetic, and 151 non-diabetic included. VivaDiagTM CO-VID-19 IgM/IgG Rapid Test was used to detect the IgM and IgG in the serum of the study group. Seroprevalence of IgM and IgG was detected in the study group, IgM seroprevalence was 84% of diabetic, 60% of prediabetic, and 92% of non-diabetic. IgG seroprevalence was 93% of diabetic, 62% of prediabetic, and 87% of non-diabetic study group. HbA1c was positively correlated with both immunoglobins indicating capability of producing one or both immunoglobins even with high HbA1c. After an additional 40 days, non-diabetic participants have double the positive immunoglobins compared to the other groups indicating optimal vaccination time for those groups is less than 50 days following recovery. Glycemic status has not affected the seroprevalence of IgM or IgG. The optimal vaccination time for diabetic patients is 40 days after the recovery from Covid-19.